CRISPR THERAPEUTICS AG Net Cash Provided by (Used in) Investing Activities, Continuing Operations
CRISPR THERAPEUTICS AG (CRSP) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$555.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-08
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$555.00K.
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$205.00K, a 101.39% decline year-over-year.
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$3.49M.
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$1.33M.
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$8.31M, a 126.08% decline from fiscal 2016.
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $31.88M.
- CRISPR THERAPEUTICS AG net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$1.15M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | -$555.00K 10-Q · filed 2018-05-08 | -$760.00K derived: sum of 2 quarters · filed 2018-05-08 | -$4.25M derived: sum of 3 quarters · filed 2018-05-08 | -$5.58M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-12-31 | -$205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$3.70M derived: sum of 2 quarters · filed 2018-03-08 | -$5.03M derived: sum of 3 quarters · filed 2018-03-08 | -$8.31M 10-K · filed 2018-03-08 |
| 2017-09-30 | -$3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$4.82M derived: sum of 2 quarters · filed 2017-11-08 | -$8.11M 10-Q · filed 2017-11-08 | $6.66M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-06-30 | -$1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$4.62M 10-Q · filed 2017-08-10 | $10.16M derived: sum of 3 quarters · filed 2018-05-08 | $8.65M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-03-31 | -$3.29M 10-Q · filed 2018-05-08 | $11.49M derived: sum of 2 quarters · filed 2018-05-08 | $9.98M derived: sum of 3 quarters · filed 2018-05-08 | $8.93M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $14.77M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $13.26M derived: sum of 2 quarters · filed 2018-03-08 | $12.22M derived: sum of 3 quarters · filed 2018-03-08 | $31.88M 10-K · filed 2018-03-08 |
| 2016-09-30 | -$1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$2.56M derived: sum of 2 quarters · filed 2017-11-08 | $17.11M 10-Q · filed 2017-11-08 | $16.61M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | -$1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $18.62M 10-Q · filed 2017-08-10 | $18.12M derived: sum of 3 quarters · filed 2018-03-08 | |
| 2016-03-31 | $19.67M 10-Q · filed 2017-05-11 | $19.16M derived: sum of 2 quarters · filed 2018-03-08 | ||
| 2015-12-31 | -$503.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$1.15M 10-K · filed 2018-03-08 | ||
| 2015-09-30 | -$651.00K 10-Q · filed 2016-11-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |